ASH 2020 | Mosunetuzumab: next-generation antibody for follicular lymphoma
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, highlights the clinical need for less cytotoxic antibodies in the treatment of follicular lymphoma (FL). Dr. Chean discusses the ongoing Phase I/Ib trial (NCT02500407) evaluating the safety and efficacy of mosunetuzumab in patients with high-risk follicular lymphoma (FL). Mosunetuzumab is a next-generation bispecific antibody targeting CD20 on B-cell lymphomas, and CD3 on T-cells to mediate cell death. The analysis showed good overall and complete response rates, with an acceptable safety profile as compared to conventional anti-CD20 antibodies. Mosunetuzumab response rates were consistent across cohorts, irrespective of patients’ high-risk profiles. The results for Mosunetuzumab are encouraging for patients with FL, and a Phase III trial exploring the therapy in combinations is planned. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
